MTAP and cancer: Researchers believe that the vulnerability of PRMT5 in MTAP‐deficient cancers may extend both upstream of PRMT5 (methionine adenosyltransferase 2A, MAT2A) and downstream of PRMT5 (RIOK1 and other PRMT5 co‐complex members).